Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients

Amerigo Boiardi, Antonio Silvani, Pier Adelchi Ruffini, Licia Rivoltini, Giorgio Parmiani, Giovanni Broggi, Andrea Salmaggi

Research output: Contribution to journalArticlepeer-review

Abstract

Nine patients with recurrent glioblastoma were given autologous adherent lymphokine-activated killer (A-LAK) cells and interleukin-2 (IL-2) administered directly into the tumor cavity through an Ommaya tube placed during surgery/biopsy. The immunotherapy was well tolerated and the response rate was 33% (one complete response, two partial responses, four with stable disease and two with progressive disease). However, survival 18 months from initial diagnosis did not differ from that reported in the literature for patients treated conventionally. Serial determinations of IL-2 in the tumor cavity during the course of treatment revealed that IL-2 concentrations were sufficient to maintain lymphocyte activation. Since steroid medication was discontinued during treatment and A-LAK cells have greater antitumor activity than standard LAK cells, other factors are discussed that might explain the limited results.

Original languageEnglish
Pages (from-to)193-197
Number of pages5
JournalCancer Immunology, Immunotherapy
Volume39
Issue number3
DOIs
Publication statusPublished - May 1994

Keywords

  • A-LAK
  • Glioblastoma
  • Loco-regional immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients'. Together they form a unique fingerprint.

Cite this